{
  "id": 20475618,
  "title": "Why Is Omeros Stock Trading Lower Tuesday?",
  "url": "https://urgent.news/2026/11/17/why-is-omeros-stock-trading-lower-tuesday",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-17T18:05:18.000Z",
  "source": {
    "name": "Benzinga",
    "slug": "benzinga",
    "url": "https://www.benzinga.com/markets/earnings/26/11/63359678/why-is-omeros-stock-trading-lower-tuesday"
  },
  "original_language": "en",
  "account": "Omeros Corporation's stock experienced a significant decline on Tuesday, following the release of mixed third-quarter 2026 financial results. While the company's adjusted earnings per share exceeded Wall Street's expectations, revenue fell short of estimates. Adjusted earnings per share reached 6 cents, surpassing the consensus estimate of 3 cents, whereas revenue was $35.93 million, missing the estimated $37.27 million. Notably, Omeros reported a net loss of $57.4 million, or 79 cents per share, up from a $30.9 million loss in the prior year. This included a noncash loss of $62 million, primarily due to mark-to-market adjustments from a derivative tied to unsecured convertible notes due in 2029. Despite these challenges, the company generated $13.3 million in positive operating cash flow during the quarter and repurchased $30.5 million in principal of its 2029 convertible notes, reducing outstanding debt and eliminating scheduled interest payments. Omeros' Yartemlea, a treatment for stem cell transplant-associated thrombotic microangiopathy, continued to generate revenue growth, with gross revenue increasing 30% to $41.8 million, although the gross-to-net adjustment rose to 14%. The company plans to expand Yartemlea's clinical development with two new studies, and remains eligible for potential milestone payments from Novo Nordisk. However, a setback in Europe, where the European Medicines Agency issued a negative opinion on Omeros' application to market Yartemlea for TA-TMA, may impact the drug's future growth prospects in that region.",
  "summary": "Omeros Corp. (NASDAQ:OMER) stock fell sharply Tuesday after the biotechnology company reported mixed third-quarter 2026 results, with adjusted earnings exceeding Wall Street expectations but revenue falling short . The company reported adjusted earnings of 6 cents per share, beating the consensus estimate of 3 cents . Revenue reached $35.93 million, missing the consensus estimate of $37.27…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}